St. Jude Medical (STJ) CEO's Take on the Global CRM Market
7/20/2012 9:05:07 AM
St. Jude Medical (NYSE:STJ) may have performed better than expected in the cardiac rhythm management business in the second quarter, but that doesn’t necessarily mean the company is confident about seeing a rosier picture around the corner. The Minnesota medical device company reported Wednesday that revenue fell 2 percent to $1.41 billion from $1.46 billion in the same period a year ago. Profits meanwhile headed the opposite direction – they climbed 1.25 percent to $244 million from 241 million in the comparable period in 2011. Earnings per share ticked up to 78 center per diluted share from 72 cents in the second quarter of last year. Most notably, the company performed better than analysts expected in its cardiac rhythm management business.
comments powered by